A new study identifies a molecule that is a probable driving force in colorectal cancer and suggests that the molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression. The researchers demonstrate that miR-135b is present at abnormally high levels in both mouse and human colorectal (CRC) tumors. The overexpression can be induced by mutations in either well-known oncogenes or tumor-suppressor genes that frequently occur in CRC, the researchers say. Read more
here.
No comments:
Post a Comment